OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance

Core Insights - OptimizeRx Corp. reported a Q3 revenue of $26.1 million, reflecting a 22% year-over-year increase, and a gross profit of $17.5 million, which is a 30% increase compared to the same period last year [1][5] Financial Performance - The company achieved a GAAP net income of $0.8 million, or $0.04 per share, in Q3 2025, compared to a net loss of $(9.1) million, or $(0.50) per share, in Q3 2024 [5][19] - Non-GAAP net income for Q3 2025 was $3.9 million, or $0.20 per diluted share, up from $2.3 million, or $0.12 per diluted share, in Q3 2024 [5][24] - Adjusted EBITDA for Q3 2025 increased to $5.1 million from $2.7 million in the same period last year [5][24] Guidance and Outlook - The company raised its full-year 2025 revenue guidance to a range of $105 million to $109 million and adjusted EBITDA guidance to between $16 million and $19 million [4][6] - For 2026, OptimizeRx introduced guidance with expected revenue between $118 million and $124 million and adjusted EBITDA between $19 million and $22 million [4][6] Key Performance Indicators - Average revenue per top 20 pharmaceutical manufacturer increased to $3.073 million in 2025 from $2.874 million in 2024 [3] - The percentage of total revenue attributable to the top 20 pharmaceutical manufacturers decreased to 56% in 2025 from 65% in 2024 [3] - Net revenue retention was reported at 120% for 2025, down from 127% in 2024 [3] Cash Position - As of September 30, 2025, cash, cash equivalents, and short-term investments totaled $19.5 million, compared to $13.4 million at the end of 2024 [5][21] Management Commentary - The CEO highlighted strong, profitable growth and an optimistic outlook for 2026, attributing success to execution, customer outcomes, and market-leading technologies [3]